CASI Pharmaceuticals, Inc. (CASIF): Operating Income

Annual figures by period end, from SEC filings.

-$45.01M

Year ended 2025-12-31

2020-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$45.01M	n/m	2026-05-15, From 2025-01-01
2024-12-31	-$39.62M	n/m	2026-05-15, From 2024-01-01
2023-12-31	-$25.08M	n/m	2026-05-15, From 2023-01-01
2022-12-31	-$34.03M	n/m	2025-03-31, From 2022-01-01
2021-12-31	-$41.52M	n/m	2024-03-28, From 2021-01-01
2020-12-31	-$52.78M	n/a	2023-04-26, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	-$45.01M	n/m
Scynexis Inc (SCYX)	2025-12-31	-$16.07M	n/m
Evofem Biosciences, Inc. (EVFM)	2025-12-31	$3.37M	n/m
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	-$7.54M	n/m
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	-$225.68M	n/m
Alumis Inc. (ALMS)	2025-12-31	-$453.80M	n/m
Entrada Therapeutics, Inc. (TRDA)	2025-12-31	-$157.90M	n/m
Celularity Inc (CELU)	2025-12-31	-$61.31M	n/m
uniQure N.V. (QURE)	2025-12-31	-$185.35M	n/m

Compare CASIF, SCYX, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗